Transgenic Mice Comprising A Constitutively-activated Mek5 And Exhibiting Cardiac Hypertrophy And Dilated Cardiomyopathy


The present invention relates to compositions and methods relating to MEK5 and its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its role molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy. In particular, inhibition of MEK5 activity will lead to decrease signalling of the pathways and reduce or eliminate the effects on sarcomere assembly, which in turn result or contribute to cardiac dysfunction. Also provided are transgenic animals and methods of screening for inhibitors of MEK5.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Aug 2, 2005
  • Application: May 30, 2002
    US US 15997102 A
  • Priority: May 30, 2002
    US US 15997102 A
  • Priority: Jun 4, 2001
    US US 29587501 P

Download Citation

Sign in to the Lens